DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Amrubicin is an investigational drug.
There have been 19 clinical trials for Amrubicin. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2008.
The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Breast Neoplasms. The leading clinical trial sponsors are Celgene Corporation, SCRI Development Innovations, LLC, and Sumitomo Dainippon Pharma Co., Ltd.
Recent Clinical Trials for Amrubicin
|Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer||Ono Pharmaceutical Co. Ltd||Phase 3|
|Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer||Bristol-Myers Squibb||Phase 3|
|A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy||Taiho Pharmaceutical Co., Ltd.||Phase 2|